Clinical trial · Interventional
Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.
Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma: a Pilot Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases (PM). It has been demonstrated to be superior to computed tomography (CT) for patients with known peritoneal disease from colorectal and gynaecological malignancies. However, the literature is scarce on the role of DWI/MRI in patients with pancreatic ductal-adenocarcinoma (PDAC). The aim of this study is to prospectively assess the added value of whole-body DWI/MRI (WB-DWI/MRI) to CT for detection of PM in the preoperative staging of patients with high-risk PDAC and evaluate how it correlates with intraoperative findings.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Adenocarcinoma | Pancreatic Adenocarcinoma | ALIAS | 0.90 |
| Pancreas Cancer, Duct Cell Adenocarcinoma | Pancreatic Carcinoma | ALIAS | 0.85 |
| Peritoneal Carcinomatosis | Peritoneal Carcinomatosis | ONTOLOGY_EXACT | 0.98 |
| Peritoneal Metastases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Whole-body diffusion-weighted magnetic resonance imaging | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- DWI-MRI
- description
- Patients to undergo DWI-MRI (patients include in the study.
- interventionNames
- Diagnostic Test: Whole-body diffusion-weighted magnetic resonance imaging
Primary outcomes (2)
- measure
- Peritoneal findings
- timeFrame
- 24 months
- description
- The number of cases in which peritoneal findings on MRI altered clinical management.
- measure
- Unexpected abortion
- timeFrame
- 24 months
- description
- The rate of unexpected aborted surgery due to peritoneal metastases discovery at surgery.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of pancreatic ductal adenocarcinoma. * Resectable disease or borderline resectable disease based on CT. * Tumor size ≥ 3 cm. * CA 19-9 ≥ 400 U/mL with normal bilirubin level (\< 40) * No evidence of distant metastases. * Patient fit for pancreatic resection (ECOG 0 or 1). Exclusion Criteria: * Impossibility to obtain tissue diagnosis preoperatively confirming pancreatic ductal adenocarcinoma. * Locally advanced disease on CT. * Tumor size \< 3 cm. * CA 19-9 \< 400 U/mL or CA 19-9 ≥ 400 U/mL with no preoperative drainage. * Suspicion of distant metastases, including peritoneal metastases, on CT. * Patient who is unable to have MRI. * Patient unfit for pancreatic resection (ECOG 2 or more).
References
Publications (19)
- BACKGROUNDBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. PMID 30207593
- BACKGROUNDDe La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014 Apr 15;89(8):626-32. PMID 24784121
- BACKGROUNDHishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006 Apr;10(4):511-8. doi: 10.1016/j.gassur.2005.09.016. PMID 16627216
- BACKGROUNDRyan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014 Sep 11;371(11):1039-49. doi: 10.1056/NEJMra1404198. No abstract available. PMID 25207767
- BACKGROUNDMizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020 Jun 27;395(10242):2008-2020. doi: 10.1016/S0140-6736(20)30974-0. PMID 32593337
- BACKGROUNDPatel CM, Sahdev A, Reznek RH. CT, MRI and PET imaging in peritoneal malignancy. Cancer Imaging. 2011 Aug 24;11(1):123-39. doi: 10.1102/1470-7330.2011.0016. PMID 21865109
- BACKGROUNDAllen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev. 2016 Jul 6;7(7):CD009323. doi: 10.1002/14651858.CD009323.pub3. PMID 27383694
- BACKGROUNDBrind'Amour A, Webb M, Parapini M, Sideris L, Segedi M, Chung SW, Chartier-Plante S, Dube P, Scudamore CH, Kim PTW. The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review. Clin Exp Metastasis. 2021 Apr;38(2):187-196. doi: 10.1007/s10585-021-10074-2. Epub 2021 Jan 24.